The National Institutes of Health has said it will conduct a randomized, controlled clinical trial in a combination of G Sciences of Gilas Inc.
remdesivir with Merck KGaA’s MRK,
interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people hospitalized due to a COVID-1
9 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration gave permission for the emergency use of remdesivir in May, many clinical trials have begun aimed at pairing investigative therapy with other drugs to see if the combination may be better. treat severe pain COVID-19 patients. This includes another NIH trial pairing remdesivir with Eli Lilly & Co. LLY,
and Incyte Corp. INCY,
Cruel. Roche Holding AG ROG,
is also said to try rheumatoid arthritis medication in conjunction with remdesivir.